Phase III
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Tremfya hit the mark in two late-stage psoriatic arthritis trials, setting the stage for another potential approval.
Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.
The primary endpoint of the study was to show that Taltz was superior to Humira in treating PsA.
Based on the results, which were not disclosed at this time, the company said it will begin to plan for regulatory approval in China.
The HOPE trial involved 274 patients with SCD from 60 institutions across 12 countries.
Texas-based Savara tried to put a positive spin on the trial and pointed to positive secondary endpoints but it wasn’t enough to please investors.
Genentech announced positive topline results from its Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug mycophenolate mofetil in patients with pemphigus vulgaris.
Companies from across the globe share business and pipeline updates.
Patients receiving Cosentyx showed no radiographic progression in almost 90% of PsA patients over two years. Of the patients receiving the drug at 150 mg, 66.3% had rapid and significant improvements in symptoms of the disease with axial manifestations at week 12.
PRESS RELEASES